These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. High dose dexamethasone as first line therapy of multiple myeloma? A case report. Meregalli M; Bertola G; Grando D Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388 [TBL] [Abstract][Full Text] [Related]
23. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062 [No Abstract] [Full Text] [Related]
24. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients? van Rhee F Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985 [No Abstract] [Full Text] [Related]
25. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
26. Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B; Smith L; Alexanian R N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971 [TBL] [Abstract][Full Text] [Related]
27. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
28. Multiple myeloma: biology and therapy. Barlogie B; Epstein J J Cancer Res Clin Oncol; 1990; 116(1):109-11. PubMed ID: 2312600 [No Abstract] [Full Text] [Related]
29. [Current perspectives in the treatment of multiple myeloma - news and views]. Knop S Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170 [No Abstract] [Full Text] [Related]
32. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study. Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809 [TBL] [Abstract][Full Text] [Related]
33. [Acute and chronic renal failure in patients with myeloma]. Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869 [TBL] [Abstract][Full Text] [Related]
34. Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Maggini V; Buda G; Galimberti S; Conidi E; Giuliani N; Morabito F; Genestreti G; Iacopino P; Rizzoli V; Barale R; Petrini M; Rossi AM Leuk Res; 2008 Jan; 32(1):49-53. PubMed ID: 17512053 [TBL] [Abstract][Full Text] [Related]
35. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network. Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G; Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479 [TBL] [Abstract][Full Text] [Related]
36. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report. Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941 [No Abstract] [Full Text] [Related]
37. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912 [TBL] [Abstract][Full Text] [Related]
38. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT]. Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148 [TBL] [Abstract][Full Text] [Related]
39. [Fatal hepatic failure due to AL amyloidosis in a patient with multiple myeloma]. Tabata S; Kurata M; Takeda J; Funayama Y; Yamauchi N; Aoki K; Kato A; Ono Y; Arima H; Takiuchi Y; Nagano S; Matsushita A; Imai Y; Ishikawa T; Takahashi T Rinsho Ketsueki; 2012 Nov; 53(11):1906-10. PubMed ID: 23257671 [TBL] [Abstract][Full Text] [Related]
40. Gastroduodenal lesions in primary AL amyloidosis. Gono T; Matsuda M; Dohi N; Sekijima Y; Tada T; Sakashita K; Koike K; Kadosaka S; Ikeda S Gastrointest Endosc; 2002 Oct; 56(4):563. PubMed ID: 12297775 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]